Sinovac registers two new not-yet-recruiting trials for PCV13 and Anflu
Sinovac entities filed registry entries for a pediatric pneumococcal lot-consistency study and a pregnancy influenza vaccine trial, both listed as not yet recruiting.
Sinovac Life Sciences and Sinovac Biotech each posted a new clinical trial registry entry, both currently listed as not yet recruiting.
- **PCV13 lot-to-lot consistency trial (Phase IIIb):** This randomized, double-blind trial will evaluate 13-valent Pneumococcal Polysaccharide Conjugate Vaccine developed by Sinovac Life Science Co., Ltd, conducted in Chinese children aged approximately 2 to 5 years.1 The study plans to enroll at least 1125 participants, randomized in a 1:1:1 ratio to receive different lots of commercially manufactured PCV13.1 Estimated start is 2026-09.
- **Anflu® influenza vaccine in pregnant women (Phase IV):** Sinovac Biotech Co., Ltd will conduct this randomized, double-blind, positive-controlled trial in Chinese pregnant women to evaluate the immunogenicity and safety of Influenza Vaccine (Split Virion), Inactivated (Anflu®).2 Participants will be randomized 2:1 to receive Anflu® or Sanofi's VAXIGRIP®.2 Estimated start is 2026-10.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.